Roche Holding AG (SWX:ROG)
Switzerland
· Delayed Price · Currency is CHF 298.40
+3.10 (1.05%)
Feb 21, 2025, 5:31 PM CET
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B
Revenue Growth
+3.23%
P/S Ratio
3.81
Revenue / Employee
604.32K
Employees
103,249
Market Cap
239.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 46.87B |
| Lonza Group AG | 6.57B |
| Alcon | 8.25B |
| Galderma Group AG | 3.88B |
| Straumann Holding AG | 2.50B |
| Sandoz Group AG | 9.09B |
| Sonova Holding AG | 3.71B |
| Ypsomed Holding AG | 617.07M |
Roche Holding AG News
- 2 days ago - Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology - GlobeNewsWire
- 3 days ago - Roche goes beyond diagnostics innovation and builds partnerships for proactive healthcare - South China Morning Post
- 4 days ago - Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche - Business Wire
- 9 days ago - Roche upgraded by UBS to buy on growth outlook - Seeking Alpha
- 10 days ago - FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA) - GlobeNewsWire
- 10 days ago - FDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA) - Business Wire
- 15 days ago - New England Journal of Medicine publishes new data for Roche's Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis - GlobeNewsWire
- 15 days ago - New England Journal of Medicine Publishes New Data for Genentech's Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis - Business Wire